Relmacabtagene autoleucel

瑞基奥仑赛

Report date: 2025/06/24 16:51:53

Base Information

Drug NameRelmacabtagene autoleucel
Drug Alias NameRelma-cel瑞基仑赛倍诺达CarteyvaJWCAR-029
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLarge B Cell LymphomaLupus Erythematosus, SystemicLymphoma, Mantle-Cell +[11] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryMainland China
Original Approved Date2021/09/01
Country/TerritoryMacauMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJw Therapeutics (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJw Therapeutics (Shanghai) Co LtdShanghai Ming Ju Biotechnology Co Ltd
Inactive CompaniesPeking UniversitySuzhou Yaomingjunuo Biotechnology Co Ltd
Active IndicationsLarge B Cell LymphomaLupus Erythematosus, SystemicLymphoma, Mantle-Cell +[8] 
Inactive IndicationsLymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeL01XX
Related LinksN/A